Shares of Pfizer Inc. (NYSE:PFE – Get Free Report) have received an average recommendation of “Hold” from the twenty-one research firms that are presently covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, fourteen have issued a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $28.3889.
A number of equities analysts recently commented on the company. UBS Group restated a “neutral” rating and set a $27.00 target price on shares of Pfizer in a report on Wednesday, May 27th. HSBC increased their target price on Pfizer from $28.00 to $30.00 and gave the company a “hold” rating in a report on Thursday, September 10th. Bank of America reduced their price objective on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research report on Friday, July 10th. Royal Bank Of Canada raised shares of Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 target price on the stock in a research report on Tuesday, June 9th. Finally, Guggenheim decreased their target price on Pfizer from $35.00 to $31.00 and set a “buy” rating for the company in a research report on Friday, August 7th.
Get Our Latest Stock Report on Pfizer
Key Headlines Impacting Pfizer
- Positive Sentiment: Investor sentiment improved after management indicated that major headwinds—including tariffs, drug-pricing pressure, declining COVID-19 revenue and upcoming patent expirations—are beginning to ease. Pfizer’s cost-reduction efforts and newer therapies could help stabilize growth. The company’s agreement to share some incremental overseas pricing revenue with the U.S. Department of Health and Human Services may also reduce policy uncertainty. How Investors Are Reacting To Pfizer Easing Policy Pressures
- Positive Sentiment: Pfizer completed a key Phase 1 study for PF-07799544, providing a pipeline milestone. Although the program remains early stage and is not an immediate earnings driver, progress could support longer-term expectations for replacement products. Pfizer Advances PF-07799544
- Positive Sentiment: Several investor analyses argue that Pfizer’s relatively low valuation and dividend yield provide downside support and leave room for a potential re-rating once post-patent-expiration performance becomes clearer. Pfizer U.S. All Stars Conference Transcript
- Neutral Sentiment: Pfizer invited investors to a November 3 conference call with analysts. The webcast is a routine communications event, but investors will look for updated guidance and commentary on the pipeline, pricing and patent losses. Pfizer November 3 Conference Call
- Neutral Sentiment: CEO Albert Bourla’s planned attendance at a White House state dinner with China’s President Xi may support visibility for Pfizer, but it has no clear near-term earnings impact. Pfizer CEO Plans State Dinner Attendance
- Negative Sentiment: Analysts remain concerned that Pfizer’s dividend is high but largely stagnant, with future appreciation dependent on successful execution after major products lose exclusivity. One commentary downgraded the stock to Hold, arguing investors may not pay for longer-term 2029 earnings until visibility improves. Pfizer Downgraded to Hold
- Negative Sentiment: Dividend-focused comparisons with Eli Lilly and AbbVie highlight Pfizer’s weaker growth profile and greater uncertainty around future earnings, limiting enthusiasm among investors seeking both income and capital appreciation. Pfizer Versus Eli Lilly for Dividend Investors
Institutional Inflows and Outflows
A number of institutional investors have recently modified their holdings of PFE. BlackRock Inc. increased its stake in shares of Pfizer by 6.3% during the second quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company’s stock worth $12,754,464,000 after acquiring an additional 31,412,883 shares during the period. State Street Corp grew its stake in Pfizer by 0.5% in the 4th quarter. State Street Corp now owns 300,445,164 shares of the biopharmaceutical company’s stock valued at $7,481,085,000 after acquiring an additional 1,357,756 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Pfizer by 0.9% in the fourth quarter. Geode Capital Management LLC now owns 130,192,081 shares of the biopharmaceutical company’s stock valued at $3,235,642,000 after purchasing an additional 1,184,728 shares during the last quarter. Norges Bank purchased a new position in Pfizer during the fourth quarter worth $1,830,986,000. Finally, Bank of New York Mellon Corp increased its position in Pfizer by 11.1% during the 1st quarter. Bank of New York Mellon Corp now owns 53,879,900 shares of the biopharmaceutical company’s stock worth $1,512,948,000 after purchasing an additional 5,364,929 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.
Pfizer Stock Up 0.6%
Shares of NYSE PFE opened at $27.92 on Friday. Pfizer has a 1 year low of $23.58 and a 1 year high of $29.21. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96. The company has a market capitalization of $159.12 billion, a P/E ratio of 36.73, a P/E/G ratio of 1.86 and a beta of 0.34. The company has a 50 day simple moving average of $26.84 and a 200-day simple moving average of $26.39.
Pfizer (NYSE:PFE – Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, beating the consensus estimate of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The business had revenue of $15.03 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same quarter in the prior year, the company posted $0.78 EPS. The company’s quarterly revenue was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities research analysts predict that Pfizer will post 2.98 earnings per share for the current year.
Pfizer Company Profile
Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its portfolio addresses a range of therapeutic areas, including oncology, inflammation and immunology, internal medicine, hospital care, rare diseases and infectious diseases. The company serves patients and healthcare providers in markets worldwide.
Pfizer’s products include the Comirnaty COVID-19 vaccine, the Prevnar family of pneumococcal vaccines, and medicines such as Eliquis, Ibrance, Vyndaqel and Zavzaret.
Read More
- Five stocks we like better than Pfizer
- Meta’s Muse Highlights Arm’s Growing Role in AI Infrastructure
- Oura’s $15.6 Billion IPO Is Betting Investors See More Than a Smart Ring
- AMD Chips Away at NVIDIA’s AI Throne
- Is the Fed Playing Chess With Rates—Or Just Behind the Curve Again?
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
